Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
1.7.1999	Evotopin	Beecham Group plc Great West Road Brentford Middlesex TW8 9BD United Kingdom	EU/1/96/028/001-003	9.7.1999
2.7.1999	Prometax	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 4AB United Kingdom	EU/1/98/092/001-012	12.7.1999
8.7.1999	Puregon	NV Organon Postbus 20 5340 BH Oss Nederland	EU/1/96/008/017-037	12.7.1999
8.7.1999	Viramune	Boehringer Ingelheim International GmbH Binger Straße 173 D-55216 Ingelheim am Rhein	EU/1/97/055/001	19.7.1999

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions realting thereto is invited to contact:

The European Agency for the Evaluation of Medicinal Products
7, Westferry Circus, Canary Wharf
London E14 4HB
United Kingdom

Summary of Community Decisions on marketing authorisations in respect of medicinal products from 15 June 1999 to 15 July 1999

(Decisions taken pursuant to Article 14 of Directive 75/319/EEC [1] or Article 22 of Directive 81/851/EEC [2])

(1999/C 218/07)

— Issuing of a national marketing authorisation

Date of the decision	Names of the medicinal product	Holders of the marketing authorisation	Member State concerned	Date of notification
18.6.1999	Aggrastat/Agrastat	See Annex A	See Annex A	23.6.1999

— Modification of a national marketing authorisation

Date of the decision	Names of the medicinal product	Holders of the marketing authorisation	Member State concerned	Date of notification
16.6.1999	Roferon-A/ Roceron-A/ Roféron-A	See Annex B	See Annex B	16.6.1999

[1] OJ L 147, 9.6.1975, p. 13, Directive last amended by Directive 93/39/EEC (OJ L 214, 24.8.1993, p. 22).
[2] OJ L 317, 6.11.1981, p. 1, Directive last amended by Directive 93/40/EEC (OJ L 214, 24.8.1993, p. 31).

ANNEX A

List of the names of the medicinal product in the Member States

Member States	Trade name	Marketing authorisation holder
Germany	Aggrastat Infusionslösungskonzentrat Aggrastat Infusionslösung	MSD Sharp & Dohme GmbH Postfach 1202, D-85530 Haar Lindenplatz 1, D-85540 Haar Mitvertrieb: MSD Chibropharm GmbH, D-85530 Haar Dieckmann Arzneimittel GmbH, D-85530 Haar
Denmark	Aggrastat	Merck Sharp & Dohme BV PO Box 581 2003 PC Haarlem Nederland Dansk repræsentant: Merck Sharp & Dohme Smedeland 8 DK-2600 Glostrup
Greece	Aggrastat	Merck & Co, Inc., Whitehouse Station, New Jersey, USA Represented by: Vianex SA Tatoioy Street PO Box 528 94 GR-14610 Nea Erithrea
France	Aggrastat	Laboratoires Merck Sharp & Dohme-Chibret 3, avenue Hoche F-75114 Paris Cedex 08
Italy	Aggrastat 0,25 Aggrastat 0,05	Merck Sharp & Dohme (Italia) SpA Via G. Fabbroni, 6 I-00191 Roma
Belgium	Aggrastat 0,25 mg/ml Aggrastat 0,05 mg/ml	Merck Sharp & Dohme BV Chaussée de Waterloo 1135 B-1180 Bruxelles
Finland	Aggrastat 0,25 mg/ml infuusiokonsentraatti, liuosta varten Aggrastat 0,05 mg/ml infuusioneste, liuos	Merck Sharp & Dohme BV Waarderweg 39 2031 BN Haarlem Nederland
Luxembourg	Aggrastat 0,25 mg/ml Aggrastat 0,05 mg/ml	Merck Sharp & Dohme BV Chaussée de Waterloo 1135 B-1180 Bruxelles/Brussel
Portugal	Aggrastat 0,25 mg/ml Aggrastat 0,05 mg/ml	Merck Sharp & Dohme, Lda Quinta da Fonte Edifício Vasco da Gama 2780-730 Paço de Arcos
Sweden	Aggrastat 0,25 mg/ml Aggrastat 0,05 mg/ml	Merck Sharp & Dohme BV PO Box 581 2003 PC Haarlem Netherlands Svenskt ombud: Merck Sharp & Dohme (Sweden) AB Box 7125 S-192 07 Sollentuna
Spain	Aggrastat 0,25 mg/ml Aggrastat 0,05 mg/ml	Merck Sharp & Dohme de España, SA Josefa Valcárcel, 38 E-28027 Madrid

Member States	Trade name	Marketing authorisation holder
Ireland	Aggrastat concentrate for solution for infusion 0.25 mg/ml Aggrastat solution for infusion 0.05 mg/ml	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Herts EN11 9 BU
United Kingdom	Aggrastat concentrate for solution for infusion 0.25 mg/ml Aggrastat solution for infusion 0.05 mg/ml	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Herts EN11 9 BU
Austria	Aggrastat Konzentrat zur Infusionsbereitung Aggrastat Infusionslösung	Merck Sharp & Dohme GmbH Donau-City Straße 6 A-1220 Wien
Netherlands	Aggrastat 0,25 mg/ml Concentraat, concentraat voor oplossing voor intraveneuze infusie Aggrastat 0,05 mg/ml Oplossing, oplossing voor intraveneuze infusie	Merck Sharp & Dohme BV Postbus 581 2003 PC Haarlem Nederland

ANNEX B

List of the marketing authorisation holders and trade name of the medicinal product in the Member States

Marketing authorisation holders for Roferon-A

Member State	Trade name	Marketing authorisation holder
Austria	Roferon-A	Roche Austria GmbH, Engelhorngasse 3, A-1211 Wien
Belgium/Luxembourg	Roferon-A	Roche SA, rue Dante 75, B-1070 Bruxelles
Denmark	Roceron-A	Roche a/s, Industriholmen 59, DK-2650 Hvidovre
United Kingdom/Ireland	Roferon-A	Roche Products Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AY, United Kingdom
Finland	Roferon-A	Roche Oy, Sinimäentie 10 A, PO Box 12, FIN-02631 Espoo
France	Roféron-A	Produits Roche, 52, Boulevard du Parc, F-92521 Neuilly-sur-Seine
Germany	Roferon-A	Hoffmann-La Roche AG, Emil-Barell-Straße 1, D-79639 Grenzach-Wyhlen
Italy	Roferon-A	Roche SpA, Piazza Durante 11, I-20131 Milano
Netherlands	Roferon-A	Roche Nederland BV, Postbus 42, 3640 AA Mijdrecht
Portugal	Roferon-A	Roche Farmacêutica Química Lda Estrada Nacinal 249, 1, P-2720 Amadora
Spain	Roferon-A	Productos Roche, SA Josefa Valcárcel, 42, E-28027 Madrid
Sweden	Roferon-A	Roche AB, PO Box 47327, S-100 74 Stockholm
Greece	Roferon-A	Roche (Hellas) SA, Alamanas 4 & Delfon St., GR-151 25 Maroussi, Attiki